The US National Institute of Allergies and Infectious Diseases has granted $US10 million in funding to pharmaceutical company Baxter Healthcare to develop a vaccine against the coronavirus causing severe acute respiratory syndrome

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1409, 2003-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Memorandum of Understanding to speed the development of malaria vaccines has been signed by the US National Institute of Allergy and Infectious Diseases and the Malaria Vaccine Initiative.

By  

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Funding in the amount of $US1 million has been pledged by US-based pharmaceutical giant Wyeth

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 365, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

A grant totalling $US16.8 million has been awarded to AlphaVax to support the development of a vaccine against HIV infections

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 437, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy

By Barnard Dale L   Kumaki Yohichi  

Future Virology, Vol. 6, Iss. 5, 2011-05 ,pp. : 615-631

Future Medicine

Access to resources Recommend Favorite

Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 7, Iss. 1, 2007-03 ,pp. : 29-41

Bentham Science Publishers

Access to resources Recommend Favorite